Polymers for reversing heparin-based anticoagulation
Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.
1. A method of counteracting heparin in a subject, the method comprising:
administering a heparin binding polymer to the subject, wherein the heparin binding polymer comprises:
a core unit, wherein the core unit comprises a C 1-18 alkyl substituted with three or more of —OR 1 ,
wherein each R 1 is independently selected from a polymer segment having monomer units of Formula (III):
wherein n is an integer from 1 to 10,000;
wherein each R 2 is independently selected from a hydrogen, carbon, a cationic moiety, R 1 , and a polymer segment of Formula (IV):
wherein each R 3 is independently selected from an oxygen cationic moiety, a hydroxyl, and a polymer segment of Formula (IV),
wherein m is an integer from 1 to 10,000
wherein each R 4 is independently selected from a C 1-6 alkoxy,
wherein the heparin binding polymer comprises 16 to 25 cationic moieties, wherein the cationic moieties have a positive charge when the heparin binding polymer is at a physiological pH,
wherein the cationic moieties are of Formula (VI):
and wherein the molecular weight of the heparin binding polymer is about 20 kDa to 25 kDa.
2. The method of claim 1 , wherein the core unit is a compound of Formula (V):
3. The method of claim 1 , wherein the polymer segment of Formula (IV):
comprises polyethylene glycol having a size of 400 Da.
4. The method of claim 1 , wherein at least one polymer segment of Formula (IV):
in the heparin binding polymer is polyethylene glycol.
5. The method of claim 1 , further comprising identifying a subject who has received an excess amount of heparin, wherein the identifying occurs before the heparin binding polymer is administered to the subject.
6. The method of claim 1 , wherein the heparin binding polymer is administered subcutaneously.
7. The method of claim 1 , wherein the heparin binding polymer is administered intravenously.
8. The method of claim 1 , wherein the heparin binding polymer binds to heparin selected from at least one of: unfractionated heparin (UFH), low molecular weight heparin (LMWH), ultra-low molecular weight heparin (ULMWH), fondaparinux, idraparinux enoxaparin, dalteparin, tinzaparin, semuloparin, or heparinoid.
9. A method of counteracting heparin in a subject, the method comprising:
administering a heparin binding polymer to the subject, wherein the heparin binding polymer comprises:
a core unit, wherein the core unit comprises a C 1-18 alkyl substituted with three or more of —OR 1 ,
wherein each R 1 is independently selected from a polymer segment having monomer units of Formula (III):
wherein n is an integer from 1 to 10,000;
wherein each R 2 is independently selected from a hydrogen, carbon, a cationic moiety, R 1 , and a polymer segment of Formula (IV):
wherein each R 3 is independently selected from an oxygen cationic moiety, a hydroxyl, and a polymer segment of Formula (IV),
wherein m is an integer from 1 to 10,000
wherein each R 4 is independently selected from a C 1-6 alkoxy,
wherein the heparin binding polymer comprises 4 to 24 cationic moieties, wherein the cationic moieties have a positive charge when the heparin binding polymer is at a physiological pH,
wherein the cationic moieties are of Formula (VI):
and wherein the molecular weight of the heparin binding polymer is about 20 kDa to 25 kDa.